

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 August 2002 (01.08.2002)

PCT

(10) International Publication Number
WO 02/058730 A2

(51) International Patent Classification?: **A61K 41/00**

(21) International Application Number: PCT/US01/51062

(22) International Filing Date: 26 October 2001 (26.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/244,850 1 November 2000 (01.11.2000) US

(71) Applicant: **ALLERGAN SALES, INC.** [US/US]; 2525 Dupont Drive, Irvine, CA 92612 (US).

(72) Inventors: **WHEELER, Larry, A.**; 18 Valley View, Irvine, CA 92612 (US). **DE VRIES, Gerald, W.**; 25142 Bautista Drive, Laguna Hills, CA 92653 (US).

(74) Agents: **FISHER, Carlos, A.** et al.; Allergan Sales, Inc., 2525 Dupont Drive, Irvine, CA 92612 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND COMPOSITIONS FOR TREATMENT OF OCULAR NEOVASCULARIZATION AND NEURAL INJURY

(57) Abstract: Methods and compositions for the treatment of ocular neovascularization and macular degeneration. The invention includes combining photodynamic therapy with administration of a neuroprotectant and a neovascularization inhibitor.

WO 02/058730 A2



17400(BAR)
DeVries et al

1

METHODS AND COMPOSITIONS FOR TREATMENT OF OCULAR
NEOVASCULARIZATION AND NEURAL INJURY

Background Of The Invention

5

Loss of visual acuity is a common problem associated with aging and with various conditions of the eye. Particularly troublesome is the development of unwanted neovascularization in the cornea, retina
10 or choroid. Choroidal neovascularization leads to hemorrhage and fibrosis, with resultant visual loss in a number of recognized eye diseases, including macular degeneration, ocular histoplasmosis syndrome, myopia, diabetic retinopathy and inflammatory diseases.

15

Age-related macular degeneration (AMD) is the leading cause of new blindness in the elderly, and choroidal neovascularization is responsible for 80% of the severe visual loss in patients with this disease. Although the natural history of the disease is
20 eventual quiescence and regression of the neovascularization process, this usually occurs at the cost of sub-retinal fibrosis and vision loss.

25

Traditional treatment of AMD relies on occlusion of the blood vessels using laser photocoagulation. However, such treatment requires thermal destruction of the neovascular tissue, and is accompanied by full-thickness retinal damage, as well as damage to medium and large choroidal vessels. Further, the subject is left with an atrophic scar and visual scotoma.

17400(BAR)
DeVries et al

2

Moreover, recurrences are common, and visual prognosis is poor.

Recent research in the treatment of neovascularization have had the aim of causing more selective closure of the blood vessels, in order to preserve the overlying neurosensory retina. One such strategy is a treatment termed photodynamic therapy or PDT, which relies on low intensity light exposure of photosensitized tissues to produce lesions in the newly developing blood vessels. In PDT, photoactive compounds are administered and allowed to reach a particular undesired tissue which is then irradiated with a light absorbed by the photoactive compound. This results in destruction or impairment of the tissue immediately surrounding the locus of the photoactive compound without the more extensive ocular tissue damage seen when photocoagulation is used.

Photodynamic therapy of conditions in the eye has been attempted over the past several decades using various photoactive compounds, e.g., porphyrin derivatives, such as hematoporphyrin derivative and Photofrin porfimer sodium; "green porphyrins", such as benzoporphyrin derivative (BPD), MA; and phthalocyanines. Photodynamic treatment of eye conditions has been reported to actually enhance the visual acuity of certain subjects. U.S. Patent No. 5,756,541.

However, although generally more safe than photocoagulation, there are certain dangers involved in performing PDT. For example, the use of low intensity lasers in conjunction with the systemic

17400(BAR)
DeVries et al

3

injection of vertporfin is currently the only approved PDT for treatment of age-related macular degeneration.

But studies have shown that the use of vertporfin at high doses (12 and 18 mg/m³) result in long term or
5 permanent scarring of the retina, chronic absence of photoreceptor cells, and optic nerve atrophy. Reinke et al., *Ophthalmology* 106:1915 (October 1999), incorporated by reference herein. At lower concentrations of vertporfin (e.g., about 6 mg/m³) PDT
10 is effective to slow vascular outgrowth somewhat, but treatment appears to be necessary every few weeks.

Pigment epithelium-derived factor (PEDF) is a polypeptide originally isolated from cultured fetal human retinal pigment epithelial (RPE) cells. See
15 Tombran-Tink et al., *Exp. Eye Res.* 53:411-414 (1991), incorporated by reference herein. PEDF and peptide fragments of PEDF have been shown to stimulate the elaboration of neuron-like processes from undifferentiated retinoblastoma cells. The PEDF
20 polypeptide has an approximate molecular weight of 50 kDa. In addition to stimulating morphological changes, PEDF induces differentiation of the retinoblastoma cells. Additionally, PEDF has recently been shown to be an angiogenic inhibitor. Dawson et al., *Science*
25 285:245 (9 July 1999), hereby incorporated by reference herein.

In vivo, PEDF is present in the normal mammalian interphotoreceptor matrix (IPM) between the neural retina and the pigment epithelium. The PEDF gene is
30 expressed early (17 weeks of gestation) in human RPE

17400(BAR)
DeVries et al

4

cells, and is thus a prime candidate as an inducer of retinal development in early development. In studies using lung fibroblast cells, the expression of PEDF (also termed EPC-1) has been found be restricted to
5 young cells in the G₀ stage of the cell cycle. In older senescent fibroblast cells PEDF transcripts are absent.

The native PEDF is thought to be a monomeric glycoprotein. The purified native protein is
10 sensitive to glycosidase F, indicating that it contains N-linked oligosaccharides. Upon glycosidase digestion, there is an approximate 3000 Dalton shift in the apparent molecular weight of the protein.

Recombinant forms of PEDF and fragments thereof
15 have been made and expressed in *E. coli* as well as mammalian cells. The amino acid sequence of human PEDF is as follows:

mgalvlllci gallghsscq npasppeegs pdpdstgalv eeedpffkvp
vnklaaavsn fgydlyrvrs smspttnvll splsvatals alslgadert
20 esiihralyy dlisspdihg tykelldttvt apqknkksas rivfekklri
kssfvaplek sygtrprvlt gnprldlqei nnwvqaqmkg klarstkeip
deisillllgv ahfkgqvwtk fdsrktsled fyldeertvr
vpmmssdpkav lryglstdls ckiaqlpltg smsiiffllpl kvtqnltlie
esltsefihd idrelktvqa vltvpklkls yegevtkslq emklqslfds
25 pdfskitgkp ikltqvehra gfewnedgag ttpspglqpa hltfpldyhl
nqpfifvlrd tdtgallfig kildprgp

This sequence has GenBank accession number AAA60058,
the GenBank sequence listing is hereby incorporated by
30 reference herein. In addition, PEDF has been isolated from a variety of other mammalian species, including

17400(BAR)
DeVries et al

5

cattle, mouse and rat; these sequences are also listed in GenBank, and are also incorporated by reference herein.

5 PEDF has a sequence homologous to members of the serpin protease inhibitor family. However, PEDF has not been shown to inhibit serine proteases like many serpins. Moreover, the protease labile loop region characteristic of serpins (which is positioned in the carboxyl terminal region of PEDF) is not necessary for
10 the neurotrophic activity of the polypeptide. Experiments have demonstrated that both protease-cleaved native and truncated recombinant forms of PEDF retain neurite differentiating activity, even when the polypeptide (normally 418 amino acids) consists only
15 of as few as the 77 N-terminus proximal residues at positions 44-121. Additionally, incubation of PEDF at 75°C does not prevent PEDF from differentiating retinoblastoma cells. Becerra et al., *J. Biol. Chem.* 270:25992 (1995), incorporated by reference herein.

20 Other neuroprotectant polypeptides have been described. For example, nerve growth factor (NGF) is a polypeptide known to have neuroprotective and neurotrophic effects. Increased survival of photoreceptors in *rd* mutant mice has been observed
25 upon intravitreal injection of purified NGF; these mice are models of retinitis pigmentosa, a condition characterized by the specific loss of photoreceptors. Lambiase et al., *Graefe's Arch. Clin. Exp. Ophthalmol.* 234:S96-S100 (1996), hereby incorporated by reference.

17400(BAR)
DeVries et al

6

Human NGF has an amino acid sequence, from amino to carboxyl terminus, as follows:

5 mqaqqyqqqr rkfaaaflaf ifilaavdta eagkkekpek kvkksdcgew
qwsvcvptsg dcglgtregt rtgaeckqtm ktqrckipcn wkkqfgaeck
yqfqawgecd lntalktrtg slkralhnae cqktvtiskp cgkltkpkpq
aeskkkkkeg kkqekmld

10 NGF sequences are available via the National Center
for Biotechnological Information
(<http://www.ncbi.nlm.nih.gov/>). This human NGF amino
acid sequence is present in the NCBI database under
Genbank Accession No. AAA35961.

15 Also, as disclosed in US Patent No. 5,958,875, a
multimeric cyclic peptide comprising a sequence of
amino acid residues or biologically functional
equivalents thereof, which are substantially
homologous to residues 29-38 of NGF, residues 43-47 of
NGF or residues 92-97 of NGF, and further comprising a
20 penicillamine residue or a cysteine residue is also
sufficient to have neurotrophic activity. This patent
is hereby incorporated by reference herein.

The growth factor ciliary neurotropic factor
(CNTF) has been shown to be effective in the
25 protection of photoreceptors in rds/rds mutant mice,
another model of retinitis pigmentosa. In one such
study, the CNTF was administered via an adenovirus
gene transfer vector containing a nucleic acid region
comprising an expressible open reading frame encoding
30 the CNTF gene. Cayouette et al., *J. Neurosci.* 18:9282
(1998), incorporated by reference herein. The

17400(BAR)

7

DeVries et al

adenovirus vector used for these studies was a replication-defective construct lacking the E1 region of the viral genome, and the CNTF gene was fused to the leader sequence of nerve growth factor which
5 directed the protein's secretion from the vector-transduced cells. The vector was administered by intravitreal injection; the amount injected was 2.9×10^7 plaque forming units (pfu) in 1 μ l. The rds/rds mice given this vector displayed greater photoreceptor
10 survival than in animals given a negative control. Additionally, the CNTF expression vector showed greater neuroprotection than in similar animals given an intravitreal injection of recombinant CNTF protein. Thus, the ability of the CNTF expression vector to
15 provide a sustained dosage of CNTF to retinal cells appears to counteract the turnover of the CNTF protein in oculo. The amino acid sequence of human CNTF is as follows:

20 maftehsplt phrrdlcsrs iwlarkirsd ltaltesyvk hqglnkninl
dsadgmpvas tdqwseltea erlqenlgay rtfhvllarl ledqqvhftp
tegdfhqaih tlllqvaafa yqieelmill eykiprnead gmpinvgdgg
lfekklwglk vlqelsqwtv rsihdlrfis shqtgiparg shyiannkkm

25 CNTF sequences are available via the National Center for Biotechnological Information
(<http://www.ncbi.nlm.nih.gov/>). This human CNTF amino acid sequence is present in the NCBI database under Genbank Accession No. UNHUCF.

30 Similar results have been described for another

17400(BAR)
DeVries et al

8

nerve cell growth factor, brain derived neurotrophic factor (BDNF). In this case, BDNF cDNA was inserted into a replication-deficient adenovirus vector and injected into the vitreous chamber of adult rats. A subpopulation of retinal glial cells, the Müller cells, expressed and secreted the recombinant BDNF; transgenic protein expression peaked at about 6-7 days following injection of the BDNF expression vector. The eyes treated with the BDNF vectors were effective to rescue injured retinal ganglion cells and these results were superior to a single injection of purified recombinant BDNF. DiPolo et al., *Proc. Natl. Acad. Sci.* 95:3978 (1998), hereby incorporated by reference herein.

15 The amino acid sequence of BDNF is given below:

mtilfltmvi syfgcmkaap mkeanirggg glaypgvrth gtlesvngpk
agsrgltsla dtfehmieel ldedqkvrpn eennkdadly tsrvmlssqv
pleppllflf eeyknyldaa nmsmrvrhrs dparrgelsv cdsisewvta
20 adkktavdms ggtvtvlekv pvskgqlkqy fyetkcnpmg ytkegcrgid
krhwnsqcert tqsyvraltm dskkrigwrf iridtsvcvt ltikrgr

BDNF sequences are available via the National Center for Biotechnological Information Website
25 (<http://www.ncbi.nlm.nih.gov/>). This human BDNF amino acid sequence is present in the NCBI database under Genbank Accession No. AAA96140.

17400(BAR)
DeVries et al

9

There are also non-peptide agents known to be neuroprotective. For example, and without limitation, the compounds brimonidine and memantine are neuroprotective agents.

5 Furthermore, there are neovascularization-inhibiting agents such as, without limitation, the tyrosine kinase inhibitors disclosed in U.S. Patent No. 6,100,254, hereby incorporated by reference herein, EMD 121974, endostatin, PTK 787, BMS 275291,
10 SU 6668, CGS 27023A, TNP 470, Vitaxin, SU 5416, thalidomide, marimastat, AG 3340, neovasat, ,anti VEGF antibody, CAI and squalamine.

15 SUMMARY OF THE INVENTION

The present invention concerns compositions and methods for the treatment of ocular neovascularization. In a preferred aspect, the
20 invention is drawn to an improved method of performing photodynamic therapy comprising treating the patient with an effective amount of a neuroprotective agent. Preferably, the neuroprotective agent is selected from the group consisting of nerve growth factor (NGF),
25 ciliary neurotrophic growth factor (CNTF), brain-derived neurotrophic factor (BDNF) and pigment epithelium-derived factor (PEDF). Even more preferably the neuroprotective agent is PEDF.

By "effective amount" of a neuroprotective agent
30 is meant an amount effective to reduce cell death among the neurons of the retina and optic nerve (e.g.,

17400(BAR)
DeVries et al

10

photoreceptors) caused by the photoactive component of PDT treatment as compared to a similarly situated PDT patient not receiving treatment with the neuroprotective agent.

5 In another embodiment, the invention is drawn to an improved method of performing photodynamic therapy comprising treating the patient with an effective amount of a neovascularization-inhibiting agent effective to protect the neurons of the retina and
10 optic nerve (e.g., photoreceptors) from damage caused by the photoactive component of PDT treatment. Preferably, the neovascularization-inhibiting agent is PEDF.

By "effective amount" of a neovascularization-inhibiting agent is meant an amount of such agent
15 effective to reduce the extent to which, or the rate at which, new blood vessels are formed in the retina of a PDT patient as compared to a similarly situated PDT patient not given the neovascularization-
20 inhibiting agent.

In a third embodiment, invention is directed to an improved method of performing photodynamic therapy comprising treating the patient with an effective
25 amount of a neovascularization-inhibiting agent, and with an effective amount of a neuroprotective agent. Preferably, both the neuroprotective agent and the neovascularization-inhibiting agent is PEDF.

In another preferred aspect, the invention is drawn to an improved method of performing photodynamic
30 therapy comprising treating the patient with an amount of PEDF effective to inhibit or block

17400(BAR)
DeVries et al

11

neovascularization so as to increase the amount of time necessary between PDT treatments and to slow the progression of ARMD and other ocular conditions in which neovascularization plays a part beyond that
5 obtained by PDT alone.

When PEDF or another agent having both neuroprotective and antiangiogenic activities is used in conjunction with PDT, it is preferred that the amount of such agent provided to PDT patients is both
10 an effective neuroprotective dose and an effective neovascularization inhibitory dose.

Determining the absolute dosage of the neuroprotective agent and/or neovascularization-inhibiting agent depends upon a number of factors,
15 including the means of administration and delivery and the form of the drug. For intraocular delivery of the purified recombinant PEDF polypeptide, CNTF polypeptide, BDNT polypeptide or NGF polypeptide (or active derivatives and fragments thereof), such as by
20 intravitreal or subretinal injection, dosages are preferably in the range of about 0.1 ug to about 100 ug per eye; more preferably in the range of about 0.20 ug to about 50 ug per eye; even more preferably in the range of about 0.5 ug to about 10 ug per eye.

25 Whether a neuroprotective agent, a neovascularization-inhibiting agent or both, the agent(s) may be delivered by any means effective to expose the retinal and optic nerve cells to the agent.

Thus, such agents may be delivered systemically, such
30 as by intravenous, intramuscular, or subcutaneous injection. Alternatively, the neuroprotective and/or

17400(BAR)
DeVries et al

12

neovascularization-inhibiting agent(s) may be delivered by direct injection into the eye, such as into the anterior chamber, posterior chamber or vitreous chamber, or by subretinal injection.

5 Another delivery method provides for sustained delivery of the polypeptide using an intraocular implant. Such implants may be, for example, a biodegradable and/or biocompatible implant or insert such as the ocular implants and inserts disclosed in
10 United States Patents No. 5,443,505, 5,824,072, 5,766,242; 4,853,224; 4,997,652; 5,164,188; 5,632,984; and 5,869,079, incorporated by reference herein. Such implants may be inserted into a chamber of the eye, such as the anterior, posterior or anterior chambers,
15 or may be implanted in the schlera, transchoroidal space, or an avascularized region exterior to the vitreous.

Other methods for the delivery of polypeptide neuroprotective and/or antiangiogenic agents, such as
20 PEDF, BDNF, CNTF, or NGF include a gene therapy vector, such as an adenovirus vector, which comprises a therapeutic nucleic acid comprising an open reading frame encoding the thereapeutic agent (or an active fragment thereof) which is capable of being expressed
25 in a target cell, such as retinal endothelium cells. Such vectors have been made and have been widely employed in basic research and in clinical trials of therapeutic proteins. In an aspect of the present invention, the delivery of the proteinacious
30 neuroprotective and/or antiangiogenic agent(s) (or therapeutic nucleic acids encoding active fragments of

17400(BAR)
DeVries et al

13

such a polypeptide agent, such as the PEDF, BDNF, NGF, CNTF or BDNF proteins or derivatives or active fragments thereof) is facilitated by delivering the vector directly to the vitreous of the eye, e.g., by
5 injection using a narrow gauge hypodermic needle or capillary tube. This mode of treatment has the advantage of delivering the therapeutic agent precisely to the desired retinal site of action, while reducing the necessary total dose as compared to
10 systemic delivery of the viral vector. Adenoviral vectors are usually capable of transient expression over a period of days or weeks. Such time periods are consistent with use in conjunction with PDT. The amount of the vector delivered may be in the order of
15 about 3.0×10^7 pfu in a volume of about 0.5-5 ul. If the initial dose is not a consideration, then a PEDF-containing expression vector may alternatively be delivered systemically, for example by intravenous infusion or intramuscular or subcutaneous injection.
20

DETAILED DESCRIPTION OF THE INVENTION

The present invention is drawn to therapeutic
25 methods and compositions for the treatment of intraocular neovascularization associated with conditions such as age-related macular degeneration (ARMD) and diabetic retinopathy.

The invention is more particularly concerned with
30 therapeutic methods combining retinal photodynamic therapy (PDT) with a neuroprotectant agent and/or an

17400(BAR)
DeVries et al

14

inhibitor of neovascularization; preferably with a single agent having both of these activities. In a preferred embodiment, the agent is a single agent having PEDF activities. In a currently more preferred aspect, the agent is human PEDF.

In a preferred aspect of this embodiment of the invention, the neuroprotective and/or antiangiogenic agent(s) are administered to the patient sufficiently prior to PDT treatment so as to be available to protect nerve cells and/or inhibit neovascularization upon the commencement of therapy. In another aspect of the invention, PEDF is administered with sufficient time to inhibit or block neovascularization occurring after PDT treatment.

Such methods are applicable to PDT treatment which makes use of any photoactive compound. Such compounds may include derivatives of hematoporphyrin, as described in U.S. Patents No. 5,028,621; 4,866,168; 4,649,151; and 5,438,071. pheophorbides are described in U.S. Pat. Nos. 5,198,460; 5,002,962; and 5,093,349; bacteriochlorins in U.S. Pat. Nos. 5,171,741 and 5,173,504; dimers and trimers of hematoporphyrins in U.S. Pat. Nos. 4,968,715 and 5,190,966. Other possible photoactive compounds include purpurins, merocyanines and porphycenes. All of the aforementioned patents are incorporated by reference herein. Of course, mixtures of photoactive compounds may be used in conjunction with each other.

A currently preferred photoactive compound is verteporfin (liposomal benzoporphyrin derivative). This compound is currently the only photoactive agent

17400(AP)
DeVries et al

15

approved by the U.S. Food and Drug Administration for treatment of choroidal neovascularization in conjunction with photodynamic therapy.

5 The photoactive agent is formulated so as to provide an effective concentration to the target ocular tissue. The photoactive agent may be coupled to a specific binding ligand which may bind to a specific surface component of the target ocular tissue, such as a cell surface receptor or, if desired, may be
10 formulated with a carrier that delivers higher concentrations of the photoactive agent to the target tissue. Exemplary ligands may be receptor antagonists or a variable region of an immunoglobulin molecule.

The nature of the formulation will depend in part
15 on the mode of administration and on the nature of the photoactive agent selected. Any pharmaceutically acceptable excipient, or combination thereof, appropriate to and compatible with the particular photoactive compound may be used. Thus, the
20 photoactive compound may be administered as an aqueous composition, as a transmucosal or transdermal composition, or in an oral formulation. The formulation may also include liposomes. Liposomal compositions are particularly preferred especially
25 where the photoactive agent is a green porphyrin. Liposomal formulations are believed to deliver the green porphyrin with a measure of selectivity to the low-density lipoprotein component of plasma which, in turn acts as a carrier to deliver the active
30 ingredient more effectively to the desired site. Increased numbers of LDL receptors have been shown to

17400(AP)
DeVries et al

16

be associated with neovascularization, and by increasing the partitioning of the green porphyrin into the lipoprotein phase of the blood, it appears to be delivered more efficiently to neovasculature.

- 5 Consistent with the chosen formulation, the photoactive compound may be delivered in a variety of ways. For example, delivery may be oral, peritoneal, rectal, or topical (e.g., by installation directly into the eye). Alternatively, delivery may be by
10 intravenous, intramuscular or subcutaneous injection.

- The dosage of the photoactive compound may vary, according to the activity of the specific compound(s) chosen, the formulation, and whether the compound is joined to a carrier and thus targeted to a specific
15 tissue as described above. When using green porphyrins, dosages are usually in the range of 0.1-50 mg/M² of body surface area; more preferably from about 1-10 mg/M² or from about 2-8 mg/M². Obviously, parameters to be considered when determining the
20 dosage include the duration and wavelength of the light irradiation and the nature of the photochemical reaction induced by the light irradiation.

- Light irradiation is performed a sufficient time after the administration of the photoactive compound
25 so as to permit the compound to reach its target tissue. Upon being irradiated with the wavelength appropriate to the compound chosen, the compound enters an excited state and is thought to interact with other compounds to form highly reactive
30 intermediates which can then destroy the target endothelial tissue, causing platelet aggregation and

17400(AP)
DeVries et al

17

thrombosis. Fluence of the irradiation may vary depending on factors such as the depth of tissue to be treated and the tissue type - generally it is between about 50 and about 200 Joules/cm². Irradiance
5 typically is between about 150 and about 900 mW/cm², but can also vary somewhat from this range.

Typically, light treatment is given about two hours following administration of the photoactive drug. In a preferred embodiment, the photoactive drug
10 is administered intravenously.

The other component(s) of the methods and composition of the present invention are a neuroprotective and/or a neovascularization-inhibiting agent. Exemplary neuroprotective agents are, without
15 exception, NGF, BDNF, CNTF and PEDF. Exemplary neovascularization-inhibiting agents are, without limitation, PEDF. NGF, BDNF, CNTF and PEDF have all been shown to have strong neurotrophic activity.

In a preferred aspect of the invention both a
20 neuroprotective and neovascularization-inhibiting agent are administered to the eye to protect it during and after PDT treatment. In an even more preferred embodiment of the invention, the neuroprotective and neovascularization-inhibiting agent is a single
25 compound. In a most preferred embodiment of the invention, the single compound is PEDF.

PEDF prolongs the life of brain neurons in culture and protects neurons against acute neurotoxic insult due to, e.g., glutamate toxicity. Thus, PEDF
30 appear to protect neurons against programmed cell death. PEDF is also an inhibitor of

17400(AP)
DeVries et al

18

neovascularization. Further, PEDF appears to promote the differentiation of immature of neural lineage into neurons and studies have shown that it is capable of deterring the onset of cellular senescence.

5 The neuroprotective and/or neovascularization-inhibiting agent(s) of the present invention are delivered in any manner in which it is effective to protect neurons and/or inhibit neovascularization incident to PDT treatment. Generally, the agent(s) is
10 administered prior to PDT treatment, so as to permit it to reach the ocular neural tissue before phototherapy. This will permit the agent(s) to have an immediate protective effect on neural cells. However, the neovascularization-inhibiting benefits of
15 an antiangiogenic agent such as PEDF can be realized even when given simultaneously with, or shortly after PDT treatment.

It will be recognized that the term PEDF means biologically active PEDF and its biologically active
20 derivatives, particularly peptides containing a region of contiguous amino acids within the region corresponding to positions 44-267, preferably within the region 44-229, most preferably within the region 44-121 of the human PEDF polypeptide. Preferably the
25 PEDF has an amino acid sequence contained in the human PEDF amino acid sequence.

Purified native, wild-type PEDF may be used as the therapeutic agent in the methods and compositions of the present invention. Bovine PEDF has been
30 purified to apparent homogeneity from the vitreous body of eyes, using an ammonium sulfate precipitation

17400(AP)
DeVries et al

19

step (45% to 80%), followed by cation exchange chromatography (e.g., Mono-S chromatography in a 100mM to 500 mM salt gradient). A similar purification protocol may be effective to purify the polypeptide
5 from human fetal retinal pigment epithelium cell culture conditioned medium.

Alternatively, the PEDF cDNA may be cloned and expressed in mammalian, insect, or bacterial cells. Recombinant human full length PEDF, and truncated
10 forms thereof have been expressed in *E. coli*; the recombinant proteins retain biological activity *in vitro* despite presumably having different or absent glycosylation from native PEDF. Purification from bacterial cells can be facilitated by permitting the
15 PEDF polypeptides to accumulate at high yield in inclusion bodies, which can then be isolated, solubilized in 4 M urea, and purified by S-Sepharose chromatography in a linear NaCl gradient.

As indicated above, PEDF may be formulated in any
20 manner effective to stabilize the polypeptide and consistent with the delivery method. Since the PEDF polypeptide has been shown to retain its biological activity upon incubation at 75° C, the core neurotrophically-active PEDF protein is hardy and
25 tolerant to formulation using methods that might tend to denature other proteins.

Additionally, PEDF may be joined, in a manner similar to that of the photoactive compounds, to cell surface targeting ligands, such as portions of an
30 antibody or immunologically active fragments to aid in

17400(AP)
DeVries et al

20

targeting the polypeptide to ocular cells, such as the optic nerve neurons and photoreceptors.

PEDF may be formulated for oral delivery in, for example, a capsule, tablet or liquid. Particularly
5 when formulated in solid form, the shelf life of the PEDF may be extended by, for example, lyophilization in an appropriate cryoprotectant. Preferred cryoprotectants are, for example, non-reducing disaccharides. A particularly preferred cryoprotectant
10 is the sugar trehalose.

PEDF may be formulated for intravenous, intramuscular, or subcutaneous injection. In such a formulation, any suitable excipient may be added to such a formulation to stabilize the active ingredient
15 and, particularly in the case of intravenous administration, to provide the necessary electrolyte balance.

PEDF may also be formulated as a suppository or otherwise administered rectally. Formulations
20 appropriate for rectal drug administration are well-known to those of skill in the art.

In yet another embodiment PEDF may be delivered as a nucleic acid encoding PEDF, which is then transcribed within the target ocular cells. This approach has
25 the advantage that a single nucleic acid may give rise to many molecules of PEDF. The PEDF-encoding nucleic acid may be formulated within liposomes. The liposomes are then able to fuse with a cell membrane, thus delivering the nucleic acid within the cell.

30 A possibly more efficient means of administering a nucleic acid encoding PEDF is through use of a viral

17400(AP)
DeVries et al

21

vector. In such a vector, the PEDF-encoding nucleic acid is expressed within the target cell and thereby the PEDF is synthesized and performs its therapeutic action *in situ*. Moreover, since the PEDF nucleic acids are delivered in a virus "package" the therapeutic nucleic acid is rendered relatively resistant to degradation by the patient's immune system or any nucleases that may be present in the blood or lymph.

Essentially, such delivery methods first involve the choice of an appropriate virus vector. There are a number of considerations in such a choice. For example, the chosen virus must be able to infect the appropriate cell type (e.g., preferably retinal epithelial cells, which can then secrete the PEDF thus produced).

Additionally, the vector itself should have low intrinsic toxicity. This term encompasses pharmacological toxicity, immune responses to the vector, the passenger gene product, or any other genes expressed by the vector *in situ*.

Studies have been performed using modified vectors derived from viruses such as adenovirus and adeno-associated virus (AAV-2). Of course, other applicable viral vectors are available or can be envisioned by the person of ordinary skill in the art; the vectors mentioned herein are by way of illustration rather than limitation.

Each prospective vector has its own properties. For example, adenovirus infections are common and

17400(AP)
DeVries et al

22

relatively benign in humans; this virus is one of those responsible for the common cold. The virus contains a double-stranded DNA genome. After deletion of non-essential genes, the virus is able to carry
5 about 8 kilobase pairs of an exogenous double-stranded DNA insert. This amount is adequate to carry PEDF coding regions and any necessary regulatory sequences, such as those responsible of the expression, processing, or secretion of the therapeutic gene
10 product. Such regulatory sequences are well known by those of ordinary skill in the art. Adenovirus does not stably integrate into the host chromosome, and therefore expression of the PEDF gene is relatively transient. Expression of the therapeutic protein in
15 adenovirus systems can be seen soon after infection. Certain constructs of adenovirus (and other gene transfer vectors) have been made "replication deficient" in order to control the extent and duration of infection.

20 AAV-2 also commonly infects humans but is not known to cause a disease. The virus is quite small, and therefore it is relatively non-immunogenic. However, the small size also means that there is less room for packaging therapeutic genes and any necessary
25 regulatory sequences. Wild-type AAV-2 stably integrates at a specific site in human chromosome 19, however the gene responsible for stable integration is deleted in recombinant versions of the viral genome, and this property is therefore lost.

30 PEDF, as indicated above, and nucleic acids encoding PEDF and variants may be administered by

17400(AP)
DeVries et al

23

systemic delivery, as by intravenous, intramuscular or subcutaneous injection. In addition, these factors may be delivered directly to the eye by biocompatible and/or biodegradable implants or inserts (such as
5 those described in patents cited and incorporated by reference above) containing the protein or nucleic acid, or by direct injection into the eye, for example by intravitreal and/or subretinal injection. Alternatively, the PEDF may be topically applied to
10 the surface in an drop.

The therapeutically effective PEDF dosage will depend upon factors including the mode of delivery, the specific activity of the polypeptide, the formulation in which the PEDF is fabricated, and the
15 form of PEDF, whether the full length polypeptide or truncated forms thereof or a nucleic acid form. Once a formulation and route of administration is decided upon, determining a therapeutically effective dose is routine in the pharmaceutical arts, and can be readily
20 determined without undue experimentation using suitable animal models such as, without limitation, non-human primates and rabbits.

Preferably, the dosage regimen of either or both the neuroprotective and antiangiogenic agent will be
25 such to permit the active agent(s) to remain in contact with retinal cells throughout the treatment period. Thus, the agent may be administered, for example, once a week for 12 weeks. If an agent is a polypeptide, like PEDF, susceptible to proteolytic
30 cleavage, the agent may be administered more frequently. An advantage of providing the agent in

17400(AP)
DeVries et al

24

the form of an expressible gene is that the frequency of administration can be reduced, as the active agent is constantly produced so long as the vector is capable of expression.

- 5 Viral vectors are constructed using standard molecular biological techniques employed by those of skill in the art. For example, U.S. Patents No. 6,083,750 and 6,077,663 are drawn to improved adenovirus-based expression vectors. These patents, including their descriptions of preparing viral
10 vectors for heterologous gene expression in mammalian cells, are hereby incorporated herein by reference.

Example 1

15

- A 74 year old patient presents with "wet" age-related macular degeneration (ARMD) in the foveal region of the right eye, and his condition is found to be suitable for photodynamic therapy (PDT). One day
20 prior to the date of scheduled treatment, the patient is given an intravenous injection of PEDF in a standard infusion solution.

- The day of scheduled PDT treatment, the patient is administered 6 mg/M² of verteporfin. Thirty
25 minutes after the start of the infusion, the patient is administered Irradiance of 600 mW/cm² and total fluence of 75 Joules/cm² from an Argon light laser. The treatment requires irradiation of the optic nerve.

- PEDF administration is continued every two days
30 throughout the 12 week evaluation period.

17400(AP)
DeVries et al

25

Evaluation of neural health is assayed 1 week, 4 weeks, and 12 weeks following treatment by visual inspection of the retina and test of visual acuity. The affected areas of the retina appear healthy with
5 no whitening (indicating lack of discernable retina damage) one week following PDT treatment; this trend continues throughout the monitoring period. Fluorescein angiography at same time points shows minimal leakage in the treated tissue after one week,
10 and this minimal leakage continues throughout the monitoring period. No evidence of renewed neovascularization can be seen 12 weeks following PDT treatment. Additionally, no evidence of optic nerve axon loss can be seen. Tests of visual acuity 4 and
15 12 weeks following combined PDT and PEDF treatment show no discernable loss of vision as a result of the treatment.

Example 2

20

Same facts as in Example 1, except that rather than being given intravenous PEDF, the patient is given a replication-deficient adenovirus vector containing an expressible PEDF gene containing the
25 signal sequence for NGF. The vector is administered by intravitreal injection three days prior to PDT treatment (3×10^7 pfu per eye in 1 ul); the vector is readministered 5 days following PDT treatment and every week thereafter for the 12 week evaluation
30 period.

17400(AP)
DeVries et al

26

Evaluation of neural health is assayed 1 week, 4 weeks, and 12 weeks following treatment by visual inspection of the retina and test of visual acuity. The affected areas of the retina appear healthy with
5 no whitening (indicating lack of discernable retina damage) one week following PDT treatment; this trend continues throughout the monitoring period. Fluorescein angiography at same time points shows minimal leakage in the treated tissue after one week,
10 and this minimal leakage continues throughout the monitoring period. No evidence of renewed neovascularization can be seen 12 weeks following PDT treatment. Additionally, no evidence of optic nerve axon loss can be seen. Tests of visual acuity 4 and
15 12 weeks following combined PDT and PEDF treatment show no discernable loss of vision as a result of the treatment.

The example illustrates certain embodiments of the
20 present invention; however, it will be understood that the invention is solely defined by the claims that conclude this specification.

17400(AP)
DeVries et al

27

CLAIMS

We claim:

- 5 1) A method for treating a mammal suffering from choroidal neovascularization, comprising administering to said patient an amount of a photoactive compound sufficient to permit an effective amount to localize in the affected target ocular tissue, then irradiating said tissue with light emitted from a laser at a wavelength sufficient to permit absorption by said photoactive compound; wherein said patient is also administered an amount of an antiangiogenic compound sufficient to inhibit recurrence of neovascularization following said irradiation.
- 10
- 15
- 20 2) The method of claim 1 wherein the antiangiogenic compound is selected from the group consisting of tyrosine kinase inhibitors and PEDF.
- 25 3) The method of claim 1 wherein said antiangiogenic compound is administered at a time sufficient to permit localization within ocular tissue prior to said irradiation.
- 30 4) The method of claim 1 wherein said antiangiogenic compound is administered intravenously.

17400(AP)
DeVries et al

28

- 5) The method of claim 1 wherein said antiangiogenic compound is administered through intraocular injection.
- 5 6) The method of claim 5 wherein said antiangiogenic compound is administered by subretinal injection.
- 7) The method of claim 5 wherein said antiangiogenic compound is administered by intravitreal
10 injection.
- 8) The method of claim 2 wherein the antiangiogenic compound is PEDF.
- 15 9) The method of any one of the preceding claims wherein said antiangiogenic compound comprises a recombinant human PEDF.
- 10) The method of claim 9 wherein said PEDF comprises
20 a continuous amino acid sequence corresponding to positions 44-121 of native human PEDF.
- 11) The method of claim 10 wherein said PEDF
25 comprises a continuous amino acid sequence corresponding to positions 44-229 of native human PEDF.
- 12) The method of claim 11 wherein said PEDF
30 comprises a continuous amino acid sequence corresponding to positions 44-267 of native human PEDF.

17400(AP)
DeVries et al

29

- 13) The method of any one of the preceding claims wherein said antiangiogenic compound is administered in the form of a composition comprising a nucleic acid which comprises an open reading frame encoding said agent and wherein said agent is expressed in ocular tissue.
- 14) The method of claim 13 wherein said composition comprises a viral coat encapsulating said nucleic acid.
- 15) The composition of claim 13 wherein said composition comprises a liposomal formulation.
- 16) A method of protecting ocular neural tissue from damage caused by photodynamic therapy (PDT) comprising delivering to a patient's ocular neural tissue an amount of a neuroprotectant compound effective to protect a plurality of ocular neurons from cell death as compared to ocular neuron cell death observed in the absence of the administration of said neuroprotectant.
- 17) The method of claim 16 wherein said neuroprotectant compound is selected from the group consisting of NGF, PEDF, CNTF, BDNF, brimonidine and memantine.
- 18) The method of claim 16 wherein said neuroprotectant compound is administered at a

17400(AP)
DeVries et al

30

time sufficiently before said PDT treatment to permit localization within ocular tissue prior to said treatment.

- 5 19) The method of claim 16 wherein said neuroprotectant compound is administered intravenously.
- 10 20) The method of claim 16 wherein said neuroprotectant compound is administered through intraocular injection.
- 15 21) The method of claim 14 wherein said neuroprotectant compound is administered by subretinal injection.
- 20 22) The method of claim 14 wherein said neuroprotectant compound is administered by intravitreal injection.
- 25 23) The method of any one of claims 16-22 wherein said neuroprotectant compound comprises a recombinant human polypeptide.
- 30 24) The method of claim 23 wherein said neuroprotectant compound comprises a continuous amino acid sequence corresponding to positions 44-121 of native human PEDF.
- 25 25) The method of claim 24 wherein said PEDF comprises a continuous amino acid sequence

17400(AP)
DeVries et al

31

corresponding to positions 44-229 of native human PEDF.

- 5 26) The method of claim 25 wherein said PEDF comprises a continuous amino acid sequence corresponding to positions 44-267 of native human PEDF.
- 10 27) The method of any one of claims 16-26 wherein said neuroprotective agent is a polypeptide and is administered in the form of a composition comprising a nucleic acid which comprises an open reading frame encoding said agent and wherein said agent is expressed in ocular tissue.
- 15 28) The method of claim 27 wherein said composition comprises a viral coat encapsulating said nucleic acid.
- 20 29) The method of claim 27 wherein said composition comprises a liposomal formulation.
- 25 30) The method of any of the preceding claims 16-29 wherein said composition also comprises an therapeutically effective amount of a antiangiogenic compound.
- 30 31) The method of claim 30 wherein said neuroprotective compound and said antiangiogenic compound are the same compound.

17400(BAR)
DeVries et al

32

- 32) The method of claim 31 wherein said compound is PEDF.
- 5 33) The method of any of the preceding claims 1-15 wherein said composition also comprises an therapeutically effective amount of a neuroprotective compound.
- 10 34) The method of claim 33 wherein said neuroprotective compound and said antiangiogenic compound are the same compound.
- 15 35) The method of claim 34 wherein said compound is PEDF.
- 36) The method of claim 34 wherein said neuroprotective compound is selected from the group consisting of brimonidine and memantine.
- 20 37) The method of claim 36 wherein said neuroprotective compound is brimonidine.
- 38) The method of claim 36 wherein said neuroprotective compound is memantine.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 August 2002 (01.08.2002)

PCT

(10) International Publication Number
WO 02/058730 A3

(51) International Patent Classification⁷: **A61K 41/00**,
31/495, C07K 14/81

(21) International Application Number: PCT/US01/51062

(22) International Filing Date: 26 October 2001 (26.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/244,850, 1 November 2000 (01.11.2000) US

(71) Applicant: **ALLERGAN, INC.** [US/US]; 2525 Dupont
Drive, Irvine, CA 92612 (US).

(72) Inventors: **WHEELER, Larry, A.**; 18 Valley View,
Irvine, CA 92612 (US). **DE VRIES, Gerald, W.**; 25142
Bautista Drive, Laguna Hills, CA 92653 (US).

(74) Agents: **FISHER, Carlos, A.** et al.; Allergan, Inc., 2525
Dupont Drive, Irvine, CA 92612 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
15 May 2003

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITIONS FOR TREATMENT OF OCULAR NEOVASCULARIZATION

(57) Abstract: Methods and compositions for the treatment of ocular neovascularization and macular degeneration. The invention includes combining photodynamic therapy with administration of a neuroprotectant and a neovascularization inhibitor.

WO 02/058730 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/51062

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K41/00 A61K31/495 C07K14/81

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, EPO-Internal, CHEM ABS Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FERRARIO A ET AL: "Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma." CANCER RESEARCH. UNITED STATES 1 AUG 2000, vol. 60, no. 15, 1 August 2000 (2000-08-01), pages 4066-4069, XP002232806 ISSN: 0008-5472 abstract; figure 4 --- -/--	1-38

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

27 February 2003

Date of mailing of the international search report

11/03/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Berte, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/51062

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DIMITROFF, CHARLES J. ET AL: "Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: Implications for combination treatment with photodynamic therapy" INVESTIGATIONAL NEW DRUGS (1999), 17(2), 121-135, XP000999614	1-38
Y	abstract; table 1	1-38
P,X	WO 01 58240 A (MASSACHUSETTS EYE AND EAR IN R) 16 August 2001 (2001-08-16) claims	1-38
P,X	CHANG J H ET AL: "Corneal neovascularization." CURRENT OPINION IN OPHTHALMOLOGY. UNITED STATES AUG 2001, vol. 12, no. 4, August 2001 (2001-08), pages 242-249, XP008014313 ISSN: 1040-8738	1
Y	abstract; table 2.3	1-38
P,X	WO 01 74389 A (NOVARTIS ERFIND VERWALT GMBH ;NOVARTIS AG (CH); BRAZZELL ROMULUS K) 11 October 2001 (2001-10-11) claims	1-38

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/51062

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-38 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; It is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/51062

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0158240	A	16-08-2001	AU 3497901 A	20-08-2001
			EP 1253943 A2	06-11-2002
			WO 0158240 A2	16-08-2001
			US 2002040015 A1	04-04-2002
WO 0174389	A	11-10-2001	AU 5040101 A	15-10-2001
			BR 0109499 A	10-12-2002
			CZ 20023174 A3	15-01-2003
			WO 0174389 A2	11-10-2001
			EP 1265636 A2	18-12-2002
			NO 20024486 A	19-09-2002
			US 2001039438 A1	08-11-2001